1. Home
  2. ICUCW vs LUMN Comparison

ICUCW vs LUMN Comparison

Compare ICUCW & LUMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUCW
  • LUMN
  • Stock Information
  • Founded
  • ICUCW N/A
  • LUMN 1968
  • Country
  • ICUCW United States
  • LUMN United States
  • Employees
  • ICUCW 19
  • LUMN N/A
  • Industry
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • LUMN Telecommunications Equipment
  • Sector
  • ICUCW Health Care
  • LUMN Telecommunications
  • Exchange
  • ICUCW Nasdaq
  • LUMN Nasdaq
  • Market Cap
  • ICUCW N/A
  • LUMN N/A
  • IPO Year
  • ICUCW 2021
  • LUMN 1972
  • Fundamental
  • Price
  • ICUCW $0.03
  • LUMN $4.22
  • Analyst Decision
  • ICUCW
  • LUMN Hold
  • Analyst Count
  • ICUCW 0
  • LUMN 9
  • Target Price
  • ICUCW N/A
  • LUMN $4.78
  • AVG Volume (30 Days)
  • ICUCW N/A
  • LUMN 10.5M
  • Earning Date
  • ICUCW N/A
  • LUMN 05-01-2025
  • Dividend Yield
  • ICUCW N/A
  • LUMN N/A
  • EPS Growth
  • ICUCW N/A
  • LUMN N/A
  • EPS
  • ICUCW N/A
  • LUMN N/A
  • Revenue
  • ICUCW N/A
  • LUMN $13,000,000,000.00
  • Revenue This Year
  • ICUCW N/A
  • LUMN N/A
  • Revenue Next Year
  • ICUCW N/A
  • LUMN N/A
  • P/E Ratio
  • ICUCW N/A
  • LUMN N/A
  • Revenue Growth
  • ICUCW N/A
  • LUMN N/A
  • 52 Week Low
  • ICUCW N/A
  • LUMN $0.97
  • 52 Week High
  • ICUCW N/A
  • LUMN $10.33
  • Technical
  • Relative Strength Index (RSI)
  • ICUCW N/A
  • LUMN 56.89
  • Support Level
  • ICUCW N/A
  • LUMN $4.24
  • Resistance Level
  • ICUCW N/A
  • LUMN $4.74
  • Average True Range (ATR)
  • ICUCW 0.00
  • LUMN 0.25
  • MACD
  • ICUCW 0.00
  • LUMN 0.09
  • Stochastic Oscillator
  • ICUCW 0.00
  • LUMN 60.99

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: